Characteristics and outcomes according to settings
| Hospitals | Community | |||||
|---|---|---|---|---|---|---|
| Characteristics | S10 (N=392) | T14 (N=391) | p Value | S10 (N=258) | T14 (N=259) | p Value |
| Gender, male % | 46.4 (182/392) | 52.4 (205/391) | 0.108 | 51.9 (134/258) | 47.5 (123/259) | 0.312 |
| Age (years, mean, SD) | 51.7 (13.2) | 50.8 (13.2) | 0.349 | 44.7 (10.4) | 48.5 (12.2) | <0.001 |
| BMI (kg/m2, mean, SD) | 24.1 (4.1) | 24.5 (4.1) | 0.149 | 24.5 (3.8) | 24.9 (3.9) | 0.178 |
| BMI ≥30 | 8.5% (33/388) | 9.8% (38/388) | 0.534 | 8.4% (21/251) | 11.5% (29/253) | 0.245 |
| Cigarette smoking | 17.6% (69/392) | 24% (94/391) | 0.033 | 18.6% (48/258) | 14.3% (37/259) | 0.185 |
| Alcohol drinking | 20.4% (80/392) | 26.6% (104/391) | 0.050 | 44.2% (114/258) | 41.7% (108/259) | 0.568 |
| Gastric ulcer | 29.2% (114/390) | 30.4% (119/391) | 0.935 | 13.9% (24/173) | 18.5% (32/173) | 0.243 |
| Duodenal ulcer | 32.8% (128/390) | 31.7% (124/391) | 0.741 | 8.7% (15/173) | 11.6% (20/173) | 0.373 |
| CYP2C19-PM | 12% (40/334) | 11.9% (40/335) | 0.989 | 16.1% (35/217) | 16.6% (37/223) | 0.896 |
| 23S rRNA mutation | 12.5% (33/264) | 7.9% (21/265) | 0.082 | 6.3% (9/144) | 8.8% (12/136) | 0.414 |
| GyrA mutation | 12.2% (30/246) | 13.4% (33/246) | 0.686 | 3.5% (5/142) | 3% (4/135) | 1.000 |
| Clarithromycin resistance | 14% (37/265) | 9% (24/266) | 0.078 | 5.5% (8/145) | 8.8% (12/136) | 0.281 |
| Metronidazole resistance | 28.7% (76/265) | 28.6% (76/266) | 0.978 | 17.2% (25/145) | 28.7% (39/136) | 0.032 |
| Amoxicillin resistance | 1.9% (5/264) | 0.8% (2/266) | 0.284 | 0.7% (1/145) | 0.7% (1/136) | 1.000 |
| Levofloxacin resistance | 14.8% (39/264) | 14.7% (39/266) | 0.971 | 2.8% (4/145) | 5.1% (7/136) | 0.302 |
| Eradication rate | ||||||
| ITT analysis, %, (N) | 88.5% (347/392) | 88% (344/391) | 0.814 | 85.3% (220/258) | 82.2% (213/259) | 0.350 |
| PP analysis, %, (N) | 93.2% (341/366) | 92.7% (341/368) | 0.789 | 89.2% (225/241) | 88.5% (207/234) | 0.795 |
| Any adverse effect | 51.5% (201/390) | 52.6% (205/390) | 0.774 | 17.5% (44/252) | 26.2% (66/252) | 0.018 |
| Took at least 80% of drugs | 96.7% (379/392) | 95.9% (375/391) | 0.565 | 95.7% (247/258) | 92.7% (240/259) | 0.135 |
| Took the drugs correctly | 97.2% (381/392) | 96.7% (378/391) | 0.674 | 96.9% (250/258) | 96.5% (250/259) | 0.811 |
| Lost to follow-up | 4.3% (17/392) | 4.3% (17/391) | 0.994 | 4.3% (11/258) | 4.2% (11/259) | 0.993 |
BMI, body mass index; ITT, intention-to-treat; N, number; PM, poor metaboliser; PP, per-protocol; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.